Accentia biopharmaceuticals announces strategic agreement

A board to discuss Revimmune as a potential therapy for multiple sclerosis
Post Reply
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm

Accentia biopharmaceuticals announces strategic agreement

Post by MSUK » Mon Nov 29, 2010 5:09 am

Accentia biopharmaceuticals announces strategic agreement with Baxter


Accentia Biopharmaceuticals, Inc. today announced a strategic agreement with Baxter Healthcare Corporation to provide Accentia with the exclusive, worldwide right to purchase Baxter's cyclophosphamide, which is marketed under the brand name Cytoxan(R), for the treatment of designated autoimmune diseases including multiple sclerosis.

Cyclophosphamide is the active drug used in Revimmune(TM) therapy, Accentia's proprietary system-of-care being developed for the treatment of a broad range of autoimmune diseases.... Read More - ... ageid/2018

Family Elder
Posts: 543
Joined: Wed Jan 03, 2007 3:00 pm
Location: Germany

Post by Frank » Mon Nov 29, 2010 11:11 am

How is this going to effect the availability of Cyclophosphamide? It is widely used for other indications e.g. cancer, immuno-ablation in ASCT, autoimmune diseases, even in MS it has already been used for a long time in a way compareable to Mitoxantrone. Will Cyclophosphamide be now only obtaineable through Accentia?
Arent there any generic versions of CTX on the market?

The original patent has long expired - will Accentia be able to get a new patent for a new indication (i.e. high dose CTX in MS)?
Is it generally possible to get new patents for an established Durg each and every time onecan prove efficacy for a new indication?

Treatment: Gilenya since 01/2011, CCSVI both IJV ballooned 09/2010, Tysabri stopped after 24 Infusions and positive JCV antibody test, after LDN, ABX Wheldon Regime for 1 year.

Post Reply
  • Similar Topics
    Last post